Close Menu

NEW YORK – Burning Rock has started a 14,000-patient trial called the Pan-Cancer Early Detection Project (PREDICT) to further validate its cell-free DNA early detection technology.

The oncology-focused, Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll thousands of patients into PREDICT with the goal of validating its cfDNA test in multiple tumor types. The test, which Burning Rock has been developing for four years, is based on its ELSA-seq technology and gauges methylation profiles.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
23
Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment.